Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B

References

• Rosner F. Hemophilia in the talmud and rabbinic writings. Ann Intern Med 1969;70(4):833-7
   PubMed Web of Science ®Google Scholar
• Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother 2005;6(9):1517-24
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Mendolicchio L, Gringeri A. Use of prophylaxis to prevent complications of hemophilia. Adv Exp Med Biol 2001;489:59-64
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232(1):25-32
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(6):535-44
   PubMed Web of Science ®Google Scholar
• Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994;47(3):208-17
   PubMed Web of Science ®Google Scholar
• Panicker J, Warrier I, Thomas R, et al. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003;9(3):272-8
   PubMed Web of Science ®Google Scholar
• Nilsson IM. Management of haemophilia in Sweden. Thromb Haemost 1976;35(3):510-21
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110(3):815-25
   PubMed Web of Science ®Google Scholar
• White GC 2nd, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The recombinate previously treated patient study group. Thromb Haemost 1997;77(4):660-7
   PubMed Web of Science ®Google Scholar
• Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian hemophilia primary prophylaxis study. J Thrombosis Haemostasis 2006;4(6):1228-36
   PubMed Web of Science ®Google Scholar
• Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001;7(4):392-6
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost 2003;29(6):585-94
   PubMed Web of Science ®Google Scholar
• Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost 2011;106(3):398-404
   PubMed Web of Science ®Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357-65
   PubMed Web of Science ®Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011;118(10):2695-701
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Shapiro A, Quon DV, et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia 2012;18(6):881-7
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012;119(3):666-72
   PubMed Web of Science ®Google Scholar
• Metzner HJ, Pipe SW, Weimer T, et al. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost 2013;110(5):931-9
   PubMed Web of Science ®Google Scholar
• Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010;115(10):2057-64
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120(12):2405-11
   PubMed Web of Science ®Google Scholar
• Schmidt SR. Fusion-proteins as biopharmaceuticals – applications and challenges. Curr Opin Drug Discov Devel 2009;12(2):284-95
   PubMedGoogle Scholar
• Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009;20(6):692-9
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715-25
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22(6):868-76
   PubMed Web of Science ®Google Scholar
• McCue J, Osborne D, Dumont J, et al. Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein. Haemophilia 2014;20(4):e327-35
   PubMed Web of Science ®Google Scholar
• Lusson J, Vieau D, Hamelin J, et al. cDNA structure of the mouse and rat subtilisin/kexin-like PC5: a candidate proprotein convertase expressed in endocrine and nonendocrine cells. Proc Natl Acad Sci USA 1993;90(14):6691-5
   PubMed Web of Science ®Google Scholar
• Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998;35(Suppl 2):11-17
   PubMed Web of Science ®Google Scholar
• Gillis S, Furie BC, Furie B, et al. Gamma-carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 1997;6(1):185-96
   PubMed Web of Science ®Google Scholar
• Phase I/IIa study of FIXFc in hemophilia B patients. Available from: http://clinicaltrials.gov/show/NCT00716716
   Google Scholar
• Lissitchkov T, Matysiak M, Zavilska K, et al. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine(R)) and a recombinant factor IX (BeneFIX(R)) in patients with severe haemophilia B. Haemophilia 2013;19(5):674-8
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013;369(24):2313-23
   PubMed Web of Science ®Google Scholar
• Study of recombinant factor IX Fc fusion protein (rFIXFc) in subjects with hemophilia B. Available from: http://clinicaltrials.gov/show/NCT01027364
   Google Scholar
• Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13(3):233-43
   PubMed Web of Science ®Google Scholar
• Powell J, Chambost H, et al. Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. ISTH Abstract 3339 J Thromb Haemost 2013;11(S2):358
   Google Scholar
• van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9(Suppl 1):27-31. discussion 31
   PubMedGoogle Scholar
• Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010;17(5):393-7
   PubMed Web of Science ®Google Scholar
• Hoffman M, Whinna HC, Monroe DM. Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. J Thromb Haemost 2006;4(9):2092-3
   PubMed Web of Science ®Google Scholar
• Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001;98(13):3600-6
   PubMed Web of Science ®Google Scholar
• Diao L, Li S, Ludden T, et al. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet 2014;53(5):467-77
   PubMed Web of Science ®Google Scholar
• Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998;4(2):83-8
   PubMed Web of Science ®Google Scholar
• Kisker CT, Eisberg A, Schwartz B, et al. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003;9(3):279-84
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003;9(Suppl 1):101-8. discussion 109-10
   PubMed Web of Science ®Google Scholar
• Ahnstrom J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10(6):689-97
   PubMed Web of Science ®Google Scholar
• Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997;94(22):11851-6
   PubMed Web of Science ®Google Scholar
• Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003;1(9):1966-71
   PubMed Web of Science ®Google Scholar
• Gale AJ, Radtke KP, Cunningham MA, et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006;4(6):1315-22
   PubMed Web of Science ®Google Scholar
• Gui T, Lin HF, Jin DY, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002;100(1):153-8
   PubMed Web of Science ®Google Scholar
• Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252(11):3578-81
   PubMed Web of Science ®Google Scholar
• Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003;55(10):1261-77
   PubMed Web of Science ®Google Scholar
• Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008;111(3):1240-7
   PubMed Web of Science ®Google Scholar
• Ngo JC, Huang M, Roth DA, et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008;16(4):597-606
   PubMed Web of Science ®Google Scholar
• Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010;116(2):270-9
   PubMed Web of Science ®Google Scholar
• Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012;12(2):235-49
   PubMed Web of Science ®Google Scholar
• Alconcel SN, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polymer Chem 2011;2(7):1442-8
   Web of Science ®Google Scholar
• Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013;19(1):11-20
   PubMed Web of Science ®Google Scholar
• Tang L, Leong L, Sim D, et al. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia 2013;19(4):539-45
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Graninger M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012;32(Suppl 1):S29-38
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013;11(4):670-8
   PubMed Web of Science ®Google Scholar
• Moss J, Rosholm A, Lauren A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011;9(7):1368-74
   PubMed Web of Science ®Google Scholar
• Goebl NA, Babbey CM, Datta-Mannan A, et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 2008;19(12):5490-505
   PubMed Web of Science ®Google Scholar
• Weimer T, Wormsbacher W, Kronthaler U, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008;99(4):659-67
   PubMed Web of Science ®Google Scholar
• Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013;131(Suppl 2):S2-6
   PubMed Web of Science ®Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007;5(9):1904-13
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012;18(10):1570-4
   PubMed Web of Science ®Google Scholar
• Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012;119(24):5871-8
   PubMed Web of Science ®Google Scholar
• Gorczyca ME, Nair SC, Jilma B, et al. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost 2012;10(8):1581-90
   PubMed Web of Science ®Google Scholar
• Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008;111(2):672-9
   PubMed Web of Science ®Google Scholar
• Knappe S, Gorczyca ME, Jilma B, et al. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood. Thromb Haemost 2013;109(3):450-7
   PubMed Web of Science ®Google Scholar
• Peraramelli S, Thomassen S, Heinzmann A, et al. Direct inhibition of factor VIIa by TFPI and TFPI constructs. J Thromb Haemost 2013;11(4):704-14
   PubMed Web of Science ®Google Scholar
• Dockal M, Brandstetter J, Ludwiczek M, et al. Peptides binding to kunitz domain 1 of tissue factor pathway inhibitor inhibit the interaction with factor Xa. J Thromb Haemost 2011;9:29-30
   Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013;11(Suppl 1):84-98
   PubMed Web of Science ®Google Scholar
• Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. J Hepatol 2013;59(6):1354-9
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Available from: www.clinicaltrials.gov
   Google Scholar